The Herald on Sunday

Prozac nation With one in five Scots on anti-depressant­s, new research reveals ‘no good evidence’ for long-term use

Concerning new medical review claims existing medical guidiance on how long patients should take medication is ‘flawed’ – and that the withdrawal process needs ‘urgent attention’

- By Helen McArdle Health Correspond­ent

THERE is “probably no good evidence” for long-term use of antidepres­sants but very little research into how patients can discontinu­e treatment safely, according to one of the academics behind a major new review into the drugs.

Dr Mark Horowitz, a research fellow and psychiatri­st-in-training at University College London who has studied the neurobiolo­gy of antidepres­sants, said studies have consistent­ly failed to distinguis­h between disease relapse and withdrawal symptoms, adding that it was “absolutely incredible” that millions of people are being left on the drugs for years.

In Scotland, more than one in five people (21.6 per cent) are being prescribed antidepres­sants and half have been taking them for more than three years.

As of 2019/20, 960,000 people in Scotland were taking antidepres­sants. The figure has increased steadily over the past decade, from 665,000 in 2010/11.

As antidepres­sants are also sometimes prescribed for non-mental health conditions – such as chronic pain or bedwetting in children – the figures provide a gauge, but not an exact count, for diagnoses of depression, anxiety, post-traumatic stress, and obsessive compulsive disorders within the population.

However, concerns about the lack of evidence to support increasing rates of long-term use have been highlighte­d in a new Cochrane Review carried out by Dr Horowitz and Belgian-based researcher and GP, Dr Ellen Van Leeuwen.

‘Scotland needs urgent attention’

COCHRANE Reviews are considered the gold standard for evaluating the reliabilit­y of evidence behind medical treatments, and are used as a guide by doctors and healthcare providers worldwide. Drs Horowitz and Van Leeuwen identified more than 1,000 studies on starting antidepres­sants but just 33 randomised control trials which examined stopping them. “It’s clear that this area needs urgent attention,” said Dr Van Leeuwen.

She added: “As a GP myself, I see firsthand the struggles many patients have coming off antidepres­sants.

“It’s of critical concern that we don’t know enough about how to reduce inappropri­ate long-term use or what the safest and most effective approaches are to help people do this.”

The issue of prescribed drug dependence and withdrawal has gained increasing attention in recent years, including through a petition brought to the Scottish Parliament in 2017 seeking help for patients harmed as a result.

It closed last month, having attracted hundreds of written submission­s in support from medical profession­als, charities and patients, some of whom described harrowing experience­s of being driven to suicide attempts as they tried to wean themselves off prescribed medication including antidepres­sants and benzodiaze­pines.

‘Panic, zaps and dread’

ALTHOUGH some patients can come off the drugs slowly and successful­ly, others experience debilitati­ng effects such as panic, dread, insomnia, agitation or “brain zaps” – sensations like electric shocks in the head and limbs.

One respondent to the petition told how withdrawal from antidepres­sants left her with “terrible panic and inner turmoil on a scale I had never encountere­d before”, eventually leading her to try to end her life.

Dr Horowitz has experience­d the problem first-hand. He has been tapering himself off antidepres­sants now for more than two years, after taking them for 18 years from the age of 21. “It’s been a very difficult process,” he told The Herald on Sunday. “As a patient, I’m very unhappy that I was not told when I started them that they would be hard to stop.”

Despite reducing the dose incrementa­lly he has still experience­d panic attacks, insomnia, and “great trouble” concentrat­ing. “I didn’t have any of those things before starting antidepres­sants. I never had trouble sleeping, never had panic attacks – I was just a mildly unhappy young man.”

Crucially, the Cochrane Review says future studies must monitor patients over a longer period (most of the tapering regimes studied lasted four weeks or less, in contrast to new guidelines from the Royal College of Psychiatri­sts which advise taking months or years to stop antidepres­sants) and all failed to disentangl­e relapse from withdrawal – a problem which has led to many realworld patients either being put back on antidepres­sants, sometimes at higher doses, or being diagnosed with new disorders.

Flawed research

DR Horowitz said the only way to avoid confusion is “to take the people off very slowly”, over months and years, so that genuine relapses can be identified. However, he added that existing guidance used by clinicians is in itself based on flawed research.

“They don’t compare people who are off the drugs to people who are on the drugs for two years,” he said. “They take people who are already on the drugs and they get half of them to stop and half to continue and then check people for relapse. And they find that they relapse more when they come off the drug.

“But they take the people off the drug over a few days, and they don’t measure withdrawal symptoms, so actually the NICE guidance saying we should be treating people for six to 12 months or two years is flawed. That’s one of the things this review is pointing towards. It’s probable that there is no good evidence for long-term treatment.”

For too long there has been a culture of denial about the problem which is

It’s been a very difficult process. As a patient myself, I’m very unhappy that I was not told when I started them that they would be hard to stop

As of 2019/20, 960,000 people in Scotland were taking antidepres­sants. The figure has increased steadily over the past decade, from 665,000 in 2010/11

unhelpful for patients, said Dr Horowitz. “Psychiatry has to stop being so defensive and crying out ‘pill shaming’ to shut down what are genuine concerns about patients’ welfare.”

There is no data yet on whether the number of people taking antidepres­sants in Scotland increased during the pandemic. Figures for England show that while antidepres­sant prescripti­ons were higher at the end of 2020 than 2019, the rate slowed compared to previous years.

The review has been welcomed by Marion Brown, a psychother­apist from Helensburg­h who brought the prescripti­on dependence petition to the Scottish Parliament after becoming concerned about the number of traumatic withdrawal experience­s among her clients.

She also believes that antidepres­sant withdrawal contribute­d to her late husband Charles’s suicide in November 2011.

The 58-year-old GP had Addison’s disease – a rare hormonal disorder which also causes depression – and had been taking the antidepres­sant Seroxat at a low dose for 25 years.

When he retired he tried to gradually stop the medication.

“It’s only now, looking back, that I recognise what was going on with him,” said Mrs Brown.

“It wasn’t something anybody talked about.

“He had terrible agitation. He couldn’t sit still. Gut problems. Terrible insomnia – he didn’t sleep for over two weeks. He kept saying ‘I want to kill myself’.

“He just felt terribly ill, physically, yet all his vital signs came out okay.

“As a doctor he’d been part of the Defeat Depression campaign in the 1990s – he’d been incentivis­ed to prescribe these drugs. He believed the hype. And we’re still living with the legacy of that because there’s so many people who have never been able to come off the drug.”

Withdrawal issues

ON March 12, the Scottish Government’s Short Life Working Group (SLWG) on prescripti­on medicine launched a consultati­on on its draft recommenda­tions, including the creation of an out-of-hours helpline for patients suffering from dependence and withdrawal symptoms, and “further research on the prevention and treatment of dependence on, and withdrawal from, prescribed medicines”.

As well as antidepres­sants, it covers tranquilis­ers such as benzodiaze­pines and Z-drugs, opioid painkiller­s, and gabapentin­oids prescribed for anxiety and nerve pain.

A spokeswoma­n for the Royal College of Psychiatri­sts in Scotland, said: “For people with depression, antidepres­sants can be a lifeline.

“Some people experience withdrawal symptoms when trying to come off them, and reducing the dose slowly before stopping can help. The more we understand about side effects, withdrawal symptoms, and how to reduce them, the more people we will be able to help.”

“That’s why it’s vital to keep engaging patients, researcher­s and mental health profession­als in an open conversati­on about the benefits and potential harms of antidepres­sants.”

 ??  ??
 ?? Dr Mark Horowitz ??
Dr Mark Horowitz
 ??  ??
 ??  ?? Marion Brown, who brought the petition to the Scottish Parliament
Marion Brown, who brought the petition to the Scottish Parliament

Newspapers in English

Newspapers from United Kingdom